Explore the evolving treatment landscape of chronic myeloid leukemia with asciminib, a promising new TKI showing high efficacy and safety.
David J. Andorsky, MD
David Andorsky, MD, is a board-certified medical oncologist and hematologist at Rocky Mountain Cancer Centers. Andorsky is an associate chair for US Oncology Hematology Research and sits on the Rocky Mountain Cancer’s Research Executive Committee.
Articles by David J. Andorsky, MD
David Andorsky, MD, discusses efficacy and safety findings from the ASC2ESCALATE study of asciminib in chronic myeloid leukemia.
David Andorsky, MD, discusses the dose escalation design of the ASC2ESCALATE study exploring asciminib's role in chronic myeloid leukemia.
David J. Andorsky, MD, discusses findings from a retrospective study of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma from ASH 2023.
David J. Andorsky, MD, discusses the findings from a subgroup analysis of patients with relapsed/refractory indolent non-Hodgkin lymphoma over the age of 70 in the phase 3b MAGNIFY clinical trial.
Latest Updated Articles
ASC2ESCALATE Clinical Trial in CML: Asciminib Dose Escalation StrategyPublished: June 16th 2025 | Updated:
- Interim Analysis Highlights Asciminib's Efficacy and Safety in Second-Line CML
Published: June 16th 2025 | Updated: